As competitive as the obesity drug market has become, Novo Nordisk's decision to slash the prices of its GLP-1 agonist drugs ...

Absent tools such as rebate reform, transparent pricing or accelerated biosimilar substitution, true price competition will ...

The Denmark-based company slashed prices for the first two monthly doses of Wegovy and Ozempic for those who pay cash for the ...

The drugmaker said it has started selling higher doses of the injectable treatment for $349 a month to patients paying the ...

Medicare Part B premiums are jumping 12% in 2026. Learn about new costs, Advantage plan cuts, and the enrollment deadline ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Trump’s GLP-1 price deal slashes costs and expands selective Medicare coverage—threatening telehealth startups and sparking a ...

The Trump administration is expected to announce deals with Eli Lilly and Novo Nordisk to cut prices of some weight loss ...

Exton, Pennsylvania-based West Pharmaceutical Services, Inc. (WST) designs, manufactures, and sells containment and delivery ...

Mitapivat met the hemoglobin endpoint but missed the endpoints for pain crises and fatigue, prompting concerns about the ...

A 2024 report found that drug prices in the U.S. were almost three times higher on average than in other high-income countries. Elise Amendola / AP The United States consistently pays more than other ...